Source-grounded facts extracted from CITIUS ONCOLOGY, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CITIUS ONCOLOGY, INC. entered into Warrant Inducement Agreement with the holder of certain existing warrants valued at approximately $11.5 million (effective 2026-05-05).
“On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants”
CITIUS ONCOLOGY, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 22, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum”
Brian Hartzband resigned as Director at CITIUS ONCOLOGY, INC..
“each of Cathy Jiang and Brian Hartzband resigned as directors”
Cathy Jiang resigned as Director at CITIUS ONCOLOGY, INC..
“each of Cathy Jiang and Brian Hartzband resigned as directors”
Taylor Zhang resigned as Chief Financial Officer at CITIUS ONCOLOGY, INC..
“Taylor Zhang resigned as Chief Financial Officer and a director”
Xiaofeng Yuan resigned as Chief Executive Officer at CITIUS ONCOLOGY, INC..
“Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board”
CITIUS ONCOLOGY, INC. incurred loan of principal amount of $66,667 with Citius Pharma at no interest maturing repayable in full per the terms of the Merger Agreement.
“On April 26, 2024, Citius Pharma deposited $66,667 into the trust account of the Company (the "Contribution") to extend the timeline to complete a business combination for an additional one (1) month period from April 18, 2024 to May 18, 2024 (the "Extension"). Such deposit of the Contribution is evidenced by an unsecured promissory note (the "Note") issued by the Company in the principal amount of $66,667 to Citius Pharma. The Note bears no interest and is repayable in full per the terms of the Merger Agreement.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.